425: TuHURA Biosciences Secures $15.5 Million in Equity Financing and Warrant Proceeds to Accelerate Immuno-Oncology Pipeline and Kineta Merger

TuHURA Biosciences, Inc. announced a definitive agreement for a $12.5 million private placement and an additional $3.0 million from warrant exercises, aimed at funding its Phase 3 trial, Kineta merger, and pipeline advancement.

Summary

• TuHURA Biosciences secured $12.5 million in commitments from a private offering of common stock and warrants.
• The private placement involved the sale of 4.6 million shares and an equal number of warrants at a combined purchase price of $2.65 per unit, representing a 15% discount to the NASDAQ closing price on June 2, 2025.
• Approximately $9.0 million of the offering is milestone-based, to be purchased in four equal tranches, with the remaining $3.5 million required by December 31, 2025.
• The initial closing of the offering is anticipated on June 4, 2025, with funding milestones expected to be achieved by the end of July 2025.
• Funding milestones include FDA notification regarding the partial clinical hold on the Phase 3 IFx-2.0 trial, initiation of the Phase 3 IFx-Hu2.0 trial, and closing of the proposed merger with Kineta, Inc.
• Additionally, the company received $3.0 million in cash proceeds from the previously disclosed February 2025 exercise of approximately 1.0 million warrants.
• The net proceeds from both the offering and warrant exercises are intended to fund the Kineta merger closing, initiate the Phase 3 Trial for IFx-2.0, advance Kineta's KVA12123 novel VISTA-inhibiting antibody to a Phase 2 trial, and cover other working capital needs.

Sentiment

Score: 7

Explanation: The announcement is largely positive due to securing significant funding ($15.5M total) to advance key clinical programs and the Kineta merger. This addresses immediate capital needs and de-risks pipeline progression. However, the 15% discount on the private placement and the existing partial clinical hold on the lead program introduce some negative sentiment and highlight ongoing challenges.

Positives

• Secured $12.5 million in new equity financing commitments, providing crucial capital.
• Received an additional $3.0 million from warrant exercises, bringing total recent funding to $15.5 million.
• Funding provides capital for the initiation of a planned Phase 3 accelerated approval trial of IFx-2.0, a key pipeline advancement.
• Funding supports the proposed acquisition of Kineta, Inc. and the initiation of a Phase 2 trial for Kineta's novel VISTA inhibiting antibody (KVA12123) in NPM1 mutated AML.
• Capital enables the advancement of first-in-class immune modulating bi-specific and bi-functional Antibody Drug Conjugates (ADC) and Antibody Peptide Conjugates (APCs).
• The company expects the combined proceeds to be sufficient to fund the Kineta merger completion, contingent on milestone satisfaction.

Negatives

• Shares and warrants in the private placement were sold at a 15% discount to the NASDAQ closing price on June 2, 2025.
• A significant portion ($9.0 million) of the $12.5 million financing is milestone-based, meaning it is not immediately available and is contingent on specific achievements.
• The company is currently subject to a partial clinical hold from the FDA on its planned Phase 3 trial of IFx-2.0, which must be lifted for a funding tranche to be released.

Risks

• Satisfaction of conditions to completing the private offering, as a portion is milestone-based.
• The impact of the proceeds from the offering may not be as anticipated or sufficient for long-term needs.
• Uncertainty regarding the anticipated regulatory pathway and timing of development programs, studies, and trials, including the Phase 3 IFx-Hu2.0 trial and the Phase 2 KVA12123 trial.
• Uncertainty regarding the closing conditions for the proposed merger transaction with Kineta, Inc.
• TuHURA's needs and expectations regarding its existing capital resources and its potential need for additional capital beyond this financing.
• Actual results or developments may differ materially from forward-looking statements due to various factors detailed in SEC filings.

Future Outlook

TuHURA Biosciences anticipates initiating a Phase 3 accelerated approval trial for IFx-2.0, targeting 40% enrollment by year-end 2025. Following the proposed merger with Kineta, the company expects to advance Kineta's novel VISTA inhibiting antibody (KVA12123) into a randomized Phase 2 trial in NPM1 Mutated r/r AML. The company also plans to advance its Delta Opioid Receptor technology for bi-specific ADCs and APCs. The proceeds from the offering and warrant exercises are expected to be sufficient to fund the Kineta merger completion, contingent on milestone satisfaction. All funding milestones for the private placement are currently anticipated to be achieved by the end of July 2025.

Management Comments

• "The Company currently anticipates that all of the Funding Milestones will be achieved by the end of July 2025."
• "The Company currently expects that the proceeds from the offering, in addition to the cash proceeds from the warrant exercises, will be sufficient to fund the Companys cash needs for completion of the Companys proposed merger with Kineta, Inc. contingent on the satisfaction of the Funding Milestones and the satisfaction of all other closing conditions and requirements relating to the completion of the merger."

Industry Context

This announcement positions TuHURA Biosciences as an active player in the immuno-oncology space, specifically targeting resistance to cancer immunotherapy, a significant challenge in current cancer treatment. The acquisition of Kineta and its VISTA inhibiting antibody broadens TuHURA's pipeline, addressing different mechanisms of immune modulation. The focus on ADCs and APCs also aligns with a growing trend in targeted cancer therapies. The financing helps secure capital for critical clinical advancements in a highly capital-intensive industry.

Comparison to Industry Standards

• The private placement at a 15% discount to market price is common for biotech companies raising capital, especially when significant portions are milestone-based, reflecting the inherent risks and future potential in early-stage drug development.
• The pursuit of a Phase 3 trial for IFx-2.0 in Merkel Cell Carcinoma (MCC) with Keytruda (pembrolizumab) positions TuHURA against established checkpoint inhibitor therapies, aiming to address primary resistance, a key unmet need. Keytruda, developed by Merck, is a leading PD-1 inhibitor.
• Advancing a VISTA inhibiting antibody (KVA12123) into Phase 2 for NPM1 Mutated r/r AML in combination with a menin inhibitor targets a specific and challenging hematological malignancy. Other companies like Gilead Sciences (through its acquisition of Forty Seven, Inc.) and Bristol Myers Squibb (through its acquisition of Celgene) have also invested in novel AML therapies.
• The development of bi-specific ADCs and APCs leveraging Delta Opioid Receptor technology is an innovative approach in the competitive ADC/APC landscape, where companies like Seagen (now part of Pfizer) and Daiichi Sankyo have set high benchmarks for targeted cancer therapies.

Stakeholder Impact

• Shareholders: Experience dilution from the private placement (4.6 million shares plus warrants) and the 15% discount on the offering price. Potential for future value creation if clinical programs succeed and the merger closes.
• Employees: Benefit from increased job security and potential for growth due to secured funding and pipeline expansion.
• Customers (Patients): Potential for new treatment options if clinical trials are successful and lead to approved therapies.
• Creditors: Benefit from improved financial stability due to the influx of new capital.
• Kineta, Inc.: The completion of the proposed merger is directly supported by this financing, impacting Kineta's future operations and integration with TuHURA.

Next Steps

• Initial closing of the private offering anticipated on June 4, 2025.
• Achievement of funding milestones (FDA clinical hold lift, Phase 3 IFx-Hu2.0 trial initiation, Kineta merger closing) anticipated by end of July 2025.
• Filing of a registration statement to register the resale of shares and underlying warrants no later than 60 calendar days following initial closing.
• Using reasonable efforts to cause the registration statement to become effective within 120 calendar days following initial closing.
• Initiation of planned Phase 3 accelerated approval trial of IFx-2.0, targeting 40% enrollment by year-end 2025.
• Closing of the proposed merger transaction with Kineta, Inc.
• Initiating a Phase 2 trial in NPM1 mutated AML for Kineta's novel VISTA inhibiting antibody (KVA12123).
• Advancing first-in-class immune modulating bi-specific and bi-functional Antibody Drug Conjugates (ADC) and Antibody Peptide Conjugates (APCs).

Key Dates

Recommendation

Keywords

TuHURA Biosciences, HURA, Kineta, Merger, Equity Financing, Private Placement, Warrant Exercise, Immuno-Oncology, Cancer Immunotherapy, IFx-2.0, Phase 3 Trial, VISTA Inhibitor, KVA12123, AML, Antibody Drug Conjugates, ADC, Antibody Peptide Conjugates, APC, Clinical Hold, FDA, Biotechnology, Pharmaceuticals, Drug Development